Cargando...
SA20. Population Pharmacokinetic Analysis and Simulations of a 2-Month Regimen for Aripiprazole Lauroxil
Background: Aripiprazole lauroxil (AL) is a prodrug of aripiprazole, formulated as an extended-release suspension approved for the treatment of schizophrenia by injection every 4 and 6 weeks. Following completion of a Phase 1 study evaluating administration of AL every 8 weeks, a pharmacokinetic (PK...
Guardado en:
| Publicado en: | Schizophr Bull |
|---|---|
| Autores principales: | , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Oxford University Press
2017
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5475906/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/schbul/sbx023.019 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|